Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
cSCC is one of the most common cancers in the U.S. and globally
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
The submission is supported by results from the Phase 3b APEX study
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Subscribe To Our Newsletter & Stay Updated
